

AF/CR

**Sterne Kessler  
Goldstein Fox**  
ATTORNEYS AT LAW



Robert Greene Sterne  
Edward J. Kessler  
Zorge A. Goldstein  
David K.S. Cornwell  
Robert W. Edmund  
Tracy-Gene G. Durkin  
Michelle A. Cimbalà  
Michael B. Ray  
Robert E. Sobush  
Eric K. Staife  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Milning  
Donald J. Featherstone  
Timothy J. Shea, Jr.  
Michael V. Messenger  
Judith U. Kim

Patrick E. Garrett  
Jeffrey T. Helvey  
Heidi L. Kraus  
Eldora L. Elton  
Thomas C. Fiala  
Albert L. Ferro  
Donald R. Banowitz  
Peter A. Jackman  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Brian J. Del Buono  
Virgil Lee Braxton  
Theodore A. Wood  
Elizabeth J. Naanes  
Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Lhullier

Rae Lynn P. Guest  
George S. Bardmesser  
Daniell A. Rein  
Jason D. Eisenberg  
Michael D. Specht  
Andria J. Kurnage  
Tracy L. Muller  
Jon E. Wright  
Lukenne M. DeSantis  
Ann E. Summerfield  
Arik W. Ledford  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gabby L. Longworth  
Lori A. Gordon  
Nicole D. Dentar  
Tad J. Gensole  
Laura A. Vogel

Michael J. Mancuso  
Bryan S. Wade  
Aaron L. Schwartz  
Michael G. Poon  
Shannon A. Carroll  
Wesley W. Jones  
Matthew E. Kelley  
Nicole R. Kzamer  
  
**Registered Patent Agents\***  
Karen R. Markowicz  
Nancy L. Leith  
Matthew J. Dowd  
Katrina Yogan Pei Quach  
Bryan L. Seltzer  
Robert A. Schwartzman  
Teresa A. Colella  
Jeffrey S. Lundgren  
Victoria S. Rutherford

Michelle K. Holokubek  
Simon J. Elliott  
Julie A. Herder  
Mita Mulheerjee  
Scott M. Woodhouse  
Christopher J. Walsh  
Liliana D. Nola-Baron  
Peter A. Socarras  
Jeffrey Mills  
  
**Of Counsel**  
Kenneth C. Bass III  
Ron R. Smith  
Marvin C. Guthrie  
  
\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Practice limited to  
Federal Agencies

August 8, 2005

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Art Unit 1642**

Re: U.S. Utility Patent Application  
Application No. 09/675,650; Filed: September 29, 2000  
For: **PCA3 Messenger RNA Species in Benign and Malignant Prostate  
Tissue**  
Inventors: Busse *et al.*  
Our Ref: 1619.0080001/JAG/CMB

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Statement of Substance of Interview; and
2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*Cynthia M. Bouchez*  
Cynthia M. Bouchez  
Attorney for Applicants  
Registration No. 47,438

JAG/CMB:krh

428772\_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Busse *et al.*

Application No.: 09/675,650

Filed: September 29, 2000

For: **PCA3 Messenger RNA Species in  
Benign and Malignant Prostate  
Tissue**

Confirmation No.: 1706

Art Unit: 1642

Examiner: Yu, Misook

Atty. Docket: 1619.0080001/JAG/CMB

**Statement of Substance of Interview**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants note that an Interview Summary has been issued in the present matter. Hence, in accordance with 37 C.F.R. § 1.133(b) and MPEP § 713.04, Applicants' undersigned representative provides the following statement of the substance of the interview held with the Examiner in the above-indicated application.


The Examiner was contacted by telephone on July 6, 2005. Applicants requested that the Examiner provide the status of the pending claims. The Examiner asked Applicants to provide support for the following clause in amended claim 4 - "wherein said isolated nucleic acid molecule is differentially expressed in a non-malignant prostate." Applicants directed the Examiner to page 5, lines 21-26 of the specification.

On the USPTO Interview Summary dated July 8, 2005, the Examiner did not indicate that agreement was not reached, so Applicants believe that the Examiner viewed Applicants' description favorably.

Applicants respectfully request that this statement be entered into the record. It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19 0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Cynthia M. Bouchez  
Attorney for Applicants  
Registration No. 47,438

Date: August 8, 2005

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

428747\_1.DOC